Literature DB >> 25174961

Proposed strategy for the use of high-dose chemotherapy with stem cell rescue and intrathecal topotecan without whole-brain irradiation for infantile classic medulloblastoma.

Ai Yamada1, Hiroshi Moritake, Sachiyo Kamimura, Shinji Yamashita, Hideo Takeshima, Hiroyuki Nunoi.   

Abstract

We describe a 6-month-old infant with classic medulloblastoma. Gross total resection of the left cerebellar tumor was performed; however, relapse occurred during the administration of intrathecal and intravenous methotrexate-based chemotherapy. After undergoing resection, high-dose chemotherapy was administered consisting of topotecan, melphalan, and cyclophosphamide with autologous peripheral stem cell rescue followed by local irradiation and intrathecal topotecan, which resulted in a complete response for more than two years. The administration of high-dose chemotherapy followed by intrathecal topotecan as maintenance therapy is an effective strategy, without losses in the cognitive function, for avoiding the use of whole-brain irradiation for infantile classic medulloblastoma.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  high-dose chemotherapy; histology; infantile medulloblastoma; intrathecal topotecan; stem cell transplantation

Mesh:

Substances:

Year:  2014        PMID: 25174961     DOI: 10.1002/pbc.25174

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Medulloblastoma.

Authors:  Nathan E Millard; Kevin C De Braganca
Journal:  J Child Neurol       Date:  2015-09-02       Impact factor: 1.987

2.  IL-17 promoted the inhibition of medulloblastoma in mice by splenocyte injection.

Authors:  Ping Zhou; Qilin Zhang; Yao Zhao; Hongying Sha; Xiaoyun Cao; Yongfei Wang
Journal:  Eur J Med Res       Date:  2015-12-18       Impact factor: 2.175

3.  Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma.

Authors:  Gregory M Shackleford; Min Y Mahdi; Rex A Moats; Debra Hawes; Hung C Tran; Jonathan L Finlay; Tuan Q Hoang; Ellis F Meng; Anat Erdreich-Epstein
Journal:  PLoS One       Date:  2019-01-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.